Studies have identified multiple molecular properties with a biological rationale supporting a role in mediating selective responses to immune-checkpoint inhibitors (ICIs), including loss-of-function mutations in mSWI/SNF chromatin regulators; however, their clinical biomarker relevance is uncertain. Herein, we evaluate emerging concepts, challenges and considerations around translating biology into biomarkers for ICIs in solid tumours setting.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Keenan, T. E., Burke, K. P. & Van Allen, E. M. Genomic correlates of response to immune checkpoint blockade. Nat. Med. 25, 389–402 (2019).
Lu, S. et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 5, 1195–1204 (2019).
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018).
Braun, D. A. et al. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. 5, 1631–1633 (2019).
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733–1741 (2020).
Hakimi, A. A. et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nat. Commun. 11, 4168 (2020).
Conway, J. et al. PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma. Preprint at medRxiv https://doi.org/10.1101/2020.10.30.20222356 (2020).
Abou Alaiwi, S. et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunol. Res. 8, 1075–1084 (2020).
Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916–1927 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.M.V.A. reports advisory relationships and consulting with Enara Bio, Genome Medical, Illumina, Invitae, Manifold Bio, Janssen and Tango Therapeutics; research support from Bristol-Myers Squibb (BMS) and Novartis; equity in Enara Bio, Genome Medical, Manifold Bio, Syapse and Tango Therapeutics; and travel reimbursement from Genentech and Roche, outside the submitted work. T.K.C. reports institutional and personal research support from Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and sons, Calithera, Cerulean, Corvus, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products, Sanofi/Aventis, Takeda and Tracon; honoraria from Alexion, American Society of Medical Oncology, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and sons, Cerulean, Clinical Care Options, Corvus, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Harborside Press, Heron Therapeutics, Ipsen, Kidney Cancer Journal, Lancet Oncology, Lilly Oncology, L-path, Merck, Michael J. Hennessy (MJH) Associates (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Navinata Healthcare, NCCN, New England Journal M, Novartis, Peloton, Pfizer, Platform Q, Prometheus Labs, Research to Practice, Roche, Roche Products, Sanofi/Aventis and Up-to-Date; consulting or advisory roles with Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and sons, Cerulean, Corvus, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Lilly Ventures, Merck, NCCN, Novartis, Peloton, Pfizer, Pionyr, Prometheus Labs, Roche, Sanofi/Aventis, Tempest and Up-to-Date; stock/option ownership in Pionyr and Tempest; present or past leadership roles as Director of GU Oncology Division at the Dana-Farber Cancer Institute (DFCI) and past President of Medical Staff at DFCI, a member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, a member of the KidneyCanAdvisory board, Kidney cancer Research Summit co-chair (2019-present); patents, royalties or other intellectual properties related to biomarkers of immune checkpoint blockers (along with E.M.V.A.) and circulating free methylated DNA; and travel, accommodations, expenses, in relation to consulting, advisory roles or honoraria.
Rights and permissions
About this article
Cite this article
Van Allen, E.M., Choueiri, T.K. Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol 18, 133–134 (2021). https://doi.org/10.1038/s41571-020-00461-1
Published:
Issue date:
DOI: https://doi.org/10.1038/s41571-020-00461-1
